TEL AVIV, Israel, Nov. 21, 2017 /PRNewswire/ --Therapix Biosciences
Ltd. (Nasdaq: TRPX) ("Therapix" or the "Company"), a specialty,
clinical-stage pharmaceutical company focusing on the development
of cannabinoid-based treatments, has received positive media
coverage in a variety of financial and trade media outlets.
A Q&A article featuring Adi Zuloff-Shani, Ph.D, Chief
Technology Officer of Therapix, was published in Drug Discovery
and Development. Titled "The 'Entourage Effect': How THC
can team up with PEA to treat symptoms of Tourette syndrome," the
article outlines the compounds involved in the Company's research
and how they potentially work together, the status of the Company's
Phase IIa clinical study for Tourette syndrome, how this treatment
will be delivered and the Company's additional focus on a therapy
for mild cognitive impairment. To read the Q&A, please visit:
https://www.dddmag.com/article/2017/11/entourage-effect-how-thc-can-team-pea-treat-symptoms-tourette-syndrome.
An article published in CFO Magazine, titled "CFO Pushes
Pharma Startup to Market," shares Therapix CFO Josh Blacher's insights on the opportunities
facing the Company as it moves forward with its clinical studies in
Tourette syndrome and sleep apnea and its preclinical data for mild
cognitive impairment. To read the article, please visit:
http://ww2.cfo.com/growth-companies/2017/11/cfo-pushes-pharma-startup-to-market-cannabinoid/.
In a podcast posted on CFO Thought Leader, titled
"Garnering Investor Recognition: Josh
Blacher, CFO, Therapix Biosciences," Mr. Blacher discusses
the importance of the therapeutic areas Therapix is working in and
the company's ongoing communications with stakeholders in the
investment, medical and scientific communities while continuing its
mission to one day provide an efficacious treatment to patients and
their caregivers. To listen to the podcast, please visit:
http://www.cfothoughtleader.com/cfopodcasts/335-garnering-investor-recognition-josh-blacher-cfo-therapix-biosciences/.
A brief published in BioCentury noted the company has
named its Chairman, Dr. Ascher
Shmulewitz, Ph.D, to the position of interim CEO. To read
the brief, please visit
https://www.biocentury.com/bc-extra/company-news/2017-11-03/management-tracks-tissue-regenix-therapix?kwh=Therapix
(subscription required).
The articles and podcast at the links above are provided for
informational purposes only. Therapix Biosciences is not
responsible for the content of the linked articles and podcast.
About Therapix Biosciences:
Therapix Biosciences Ltd. is a specialty clinical-stage
pharmaceutical company led by an experienced team of senior
executives and scientists. Our focus is creating and enhancing a
portfolio of technologies and assets based on cannabinoid
pharmaceuticals. With this focus, the Company is currently engaged
in the following drug development programs based on repurposing an
FDA approved synthetic cannabinoid (dronabinol): THX-110 and
THX-120 for the treatment of Tourette syndrome (TS) and Obstructive
Sleep Apnea (OSA); THX-130 for the treatment of Mild Cognitive
Impairment (MCI) and Traumatic Brain Injury (TBI); and THX-150 for
the treatment of infectious diseases. Please visit our website for
more information at www.therapixbio.com.
Forward-Looking Statements:
This press release contains forward-looking statements about the
Company's expectations, beliefs, and intentions. Forward-looking
statements can be identified by the use of forward-looking words
such as "believe", "expect", "intend", "plan", "may", "should",
"could", "might", "seek", "target", "will", "project", "forecast",
"continue" or "anticipate" or their negatives or variations of
these words or other comparable words or by the fact that these
statements do not relate strictly to historical matters. Such
forward-looking statements used in this press release include,
among other things, references to the clinical and commercial
potential of THX-OSA01 for the treatment of Obstructive Sleep
Apnea. Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, our ability to raise the additional funding
needed to continue to pursue our business and product development
plans, the inherent uncertainties associated with developing new
products or technologies, our ability to obtain regulatory approval
for our product candidates, our ability to commercialize our
product candidates, competition in the industry in which we operate
and overall market conditions. Any forward-looking statement in
this press release speaks only as of the date of this press
release. The Company undertakes no obligation to publicly update or
review any forward-looking statement, whether as a result of new
information, future developments or otherwise, except as may be
required by any applicable securities laws. More detailed
information about the risks and uncertainties affecting the Company
is contained under the heading "Risk Factors" in Therapix
Biosciences Ltd.'s annual report on Form 20-F dated May 1, 2017 filed with the SEC, which is
available on the SEC's website, www.sec.gov.
For further information:
Investor
Contact:
Josh Blacher, CFO,
Therapix Biosciences
+972-3-616-7055
josh@therapixbio.com
Media Contact:
Susan
Forman, DGI
+1-212-825-3210
View original
content:http://www.prnewswire.com/news-releases/therapix-biosciences-spotlighted-in-financial-and-trade-media-outlets-300560184.html
SOURCE Therapix Biosciences Ltd